2346-74-9

Basic information

• Product Name: 6-CHLORO-9-METHYLPURINE
• Synonyms: OTAVA-BB BB7216640145;6-CHLORO-9-METHYL-9H-PURINE;6-CHLORO-9-METHYLPURINE;9-METHYL-6-CHLOROPURINE;AKOS BBS-00003131;IFLAB-BB F1371-0159;NSC 4948
• CAS NO: 2346-74-9
• Molecular Formula: C₆H₅ClN₄
• Molecular Weight: 168.58
• Product Categories: pharmacetical;Nucleotides and Nucleosides;Bases & Related Reagents;Nucleotides
• Mol File: 2346-74-9.mol
• Article Data: 27

Chemical Properties

• Melting Point: 129-134oC
• Boiling Point: 321.7 °C at 760 mmHg
• Flash Point: 148.4 °C
• Appearance: pale yellow solid
• Density: 1.59 g/cm³
• Vapor Pressure: 0.000293mmHg at 25°C
• Refractive Index: 1.743
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• PKA: 1.26±0.10(Predicted)
• CAS DataBase Reference: 6-CHLORO-9-METHYLPURINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-9-METHYLPURINE(2346-74-9)
• EPA Substance Registry System: 6-CHLORO-9-METHYLPURINE(2346-74-9)

Safety Data

• Hazardous Substances Data: 2346-74-9(Hazardous Substances Data)

Usage

Description

6-CHLORO-9-METHYLPURINE is a pale yellow solid that serves as a useful synthetic intermediate in the chemical industry. It is a derivative of purine, an important compound in biochemistry, and is characterized by the presence of a chlorine atom at the 6th position and a methyl group at the 9th position in its molecular structure.

Uses

1. Used in Pharmaceutical Industry:
6-CHLORO-9-METHYLPURINE is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its unique chemical structure allows it to be a key component in the synthesis of drugs targeting specific biological pathways.
2. Used in Chemical Research:
6-CHLORO-9-METHYLPURINE is also utilized in chemical research as a starting material for the synthesis of novel compounds with potential applications in various fields, including materials science, agrochemistry, and environmental science.
3. Used in Biochemical Studies:
Due to its structural similarity to purine, 6-CHLORO-9-METHYLPURINE can be employed in biochemical studies to investigate the effects of structural modifications on the biological activity of purine-based compounds. This can lead to a better understanding of the molecular mechanisms underlying various biological processes and the development of targeted therapeutics.

Synthesis Reference(s)

Journal of the American Chemical Society, 79, p. 490, 1957 DOI: 10.1021/ja01559a069

InChI:InChI=1/C6H5ClN4/c1-11-3-10-4-5(7)8-2-9-6(4)11/h2-3H,1H3

Upstream product

• 122-51-0 orthoformic acid triethyl ester 
• 52602-68-3 6-chloro-N⁴-methylpyrimidine-4,5-diamine 
• 87-42-3 6-chloropurine 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 87-42-3 6-chloro-7H-purine 
• 74-83-9 methyl bromide 
• 74-87-3 methylene chloride 

Downstream Products

• 35234-62-9 6-Propylamino-9-methylpurin 
• 1127-75-9 9-methyl-6-methylthiopurine 
• 5400-01-1 N⁶-ethyl-9-methyladenine 
• 3013-82-9 6-N,N-dimethyl-9-methyladenine 
• 5418-12-2 isopropyl-(9-methyl-9H-purin-6-yl)-amine 
• 1006-20-8 9-methyl-1,9-dihydro-6H-purine-6-thione 
• 2009-52-1 N₆,N₉-dimethyladenine 
• 100124-22-9 6-(4-bromo-phenoxy)-9-methyl-9H-purine 
• 5401-70-7 9-methyl kinetin 
• 109292-99-1 (9-Methyl-9H-purin-6-yl)-(2-thiophen-3-yl-ethyl)-amine 
• 109292-95-7 N₆-2-Fluorophenyl-9-methyladenine 
• 109293-01-8 N⁶-(1-phenyl-2(S)-propyl)-9-methyladenine 
• 135394-02-4 (2,2-Diphenyl-ethyl)-(9-methyl-9H-purin-6-yl)-amine 
• 109293-00-7 N⁶-(1-phenyl-2(R)-propyl)-9-methyladenine 

Relevant articles and documents

Synthesis of N6-[endo-2′-(endo-5′-hydroxy)norbornyl] -8-(N-methylisopropylamino)-9-methyladenine (WRC-0571): A potent and selective adenosine A1 receptor antagonist

A new versatile synthesis of N6-[endo-2′-(endo-5′- hydroxy)norbornyl]-8-(N-methylisopropylamino)-9-methyladenine (WRC-0571), a highly potent and selective antagonist for adenosine A1 receptor, is presented. The overall yield is 14%.

-

-

Regioselective alkylation reaction of purines under microwave irradiation

The alkylation of purines which is generally carried out after anion formation by treatment with a base and alkyl halide is complicated and in the best cases, mixtures of N-alkylated compounds are obtained. Purine derivatives can be acquired from alkylati

Projected Dose Optimization of Amino- And Hydroxypyrrolidine Purine PI3KδImmunomodulators

The approvals of idelalisib and duvelisib have validated PI3Kδinhibitors for the treatment for hematological malignancies driven by the PI3K/AKT pathway. Our program led to the identification of structurally distinct heterocycloalkyl purine inhibitors wit

ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF

Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.